Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
|
|
Loxo Oncology, Inc. (LOXO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/08/2020 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 0% stake in Loxo Oncology, Inc. |
| 02/25/2019 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 02/22/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/15/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/15/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/15/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/15/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/15/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/15/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/15/2019 |
8-K
| Quarterly results |
| 02/15/2019 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 02/15/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/15/2019 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/15/2019 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 02/15/2019 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 02/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/15/2019 |
4
| Nanda Nisha (Chief Development Officer) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Disposed/sold 18,896 shares
@ $235, valued at
$4.4M
Disposed/sold 16,983 options to buy
@ $1.184, valued at
$20.1k
Disposed/sold 14,828 options to buy
@ $1.184, valued at
$17.6k
Disposed/sold 4,557 options to buy
@ $3.648, valued at
$16.6k
Disposed/sold 10,861 options to buy
@ $13.67, valued at
$148.5k
Disposed/sold 9,228 options to buy
@ $31.69, valued at
$292.4k
Disposed/sold 14,870 options to buy
@ $27, valued at
$401.5k
Disposed/sold 18,375 options to buy
@ $26.27, valued at
$482.7k
Disposed/sold 12,000 options to buy
@ $43.56, valued at
$522.7k
Disposed/sold 75,000 options to buy
@ $84.88, valued at
$6.4M
Disposed/sold 37,000 options to buy
@ $139.77, valued at
$5.2M
|
|
| 02/15/2019 |
4
| Naider Avi Z. (Director) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Gifted 15,000 shares
@ $0
Disposed/sold 111,843 shares
@ $235, valued at
$26.3M
Disposed/sold 15,625 options to buy
@ $13, valued at
$203.1k
Disposed/sold 7,812 options to buy
@ $20.91, valued at
$163.3k
Disposed/sold 7,812 options to buy
@ $24.18, valued at
$188.9k
Disposed/sold 11,000 options to buy
@ $78.58, valued at
$864.4k
Disposed/sold 8,750 options to buy
@ $180.98, valued at
$1.6M
|
|
| 02/15/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 02/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/15/2019 |
4
| Flaherty Keith T. (Director) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Disposed/sold 9,732 shares
@ $235, valued at
$2.3M
Disposed/sold 32,345 options to buy
@ $1.184, valued at
$38.3k
Disposed/sold 68,620 options to buy
@ $1.184, valued at
$81.2k
Disposed/sold 31,459 options to buy
@ $3.648, valued at
$114.8k
Disposed/sold 15,625 options to buy
@ $13, valued at
$203.1k
Disposed/sold 12,500 options to buy
@ $13.67, valued at
$170.9k
Disposed/sold 7,812 options to buy
@ $20.91, valued at
$163.3k
Disposed/sold 7,812 options to buy
@ $24.18, valued at
$188.9k
Disposed/sold 11,000 options to buy
@ $78.58, valued at
$864.4k
Disposed/sold 2,500 options to buy
@ $84.88, valued at
$212.2k
Disposed/sold 8,750 options to buy
@ $180.98, valued at
$1.6M
|
|
| 02/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/15/2019 |
4
| Burstein Jennifer (Senior VP of Finance) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Disposed/sold 17,500 options to buy
@ $11.35, valued at
$198.6k
Disposed/sold 28,000 options to buy
@ $26.27, valued at
$735.6k
Disposed/sold 28,000 options to buy
@ $31.69, valued at
$887.3k
Disposed/sold 12,000 options to buy
@ $43.56, valued at
$522.7k
Disposed/sold 40,000 options to buy
@ $84.88, valued at
$3.4M
Disposed/sold 20,000 options to buy
@ $139.77, valued at
$2.8M
|
|
| 02/15/2019 |
4
| Bilenker Joshua H. (President & CEO) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Disposed/sold 162,707 shares
@ $235, valued at
$38.2M
Disposed/sold 30,000 shares
@ $235, valued at
$7.1M
Disposed/sold 27,459 options to buy
@ $1.184, valued at
$32.5k
Disposed/sold 64,471 options to buy
@ $3.648, valued at
$235.2k
Disposed/sold 318,514 options to buy
@ $13.67, valued at
$4.4M
Disposed/sold 142,000 options to buy
@ $31.69, valued at
$4.5M
Disposed/sold 209,000 options to buy
@ $26.27, valued at
$5.5M
Disposed/sold 100,000 options to buy
@ $43.56, valued at
$4.4M
Disposed/sold 300,000 options to buy
@ $84.88, valued at
$25.5M
Disposed/sold 128,000 options to buy
@ $139.77, valued at
$17.9M
|
|
| 02/14/2019 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 6.9% stake in Loxo Oncology, Inc. |
| 02/13/2019 |
SC 13G/A
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 0% stake in Loxo Oncology, Inc. |
| 02/12/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2019 |
SC 13G/A
| VANGUARD GROUP INC reports a 9.1% stake in Loxo Oncology Inc |
| 02/11/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|
|
|